AdAlta Ltd
1AD
Company Profile
Business description
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation protein and cell-based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
Contact
Science Drive
La Trobe Institute for Molecular Science, Room 204, LIMS2
La Trobe University
BundooraVIC3086
AUST: +61 394795159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
12
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,002.00 | 60.50 | 0.68% |
| CAC 40 | 7,744.41 | 53.81 | -0.69% |
| DAX 40 | 24,041.90 | 265.90 | -1.09% |
| Dow JONES (US) | 44,502.44 | 179.37 | 0.40% |
| FTSE 100 | 9,023.81 | 10.82 | 0.12% |
| HKSE | 25,401.16 | 271.13 | 1.08% |
| NASDAQ | 20,892.69 | 81.49 | -0.39% |
| Nikkei 225 | 41,089.49 | 1,314.57 | 3.31% |
| NZX 50 Index | 12,756.68 | 77.06 | -0.60% |
| S&P 500 | 6,309.62 | 4.02 | 0.06% |
| S&P/ASX 200 | 8,739.60 | 62.40 | 0.72% |
| SSE Composite Index | 3,608.58 | 26.71 | 0.75% |